businessbriefs
9:46in productionCh. 1 · The Merger Was Not a Pivot/ 9:46 · ceiling 15 min
Companies

Bristol Myers Squibb

1989

A 1989 merger of two penicillin-makers became a US-revenue monoculture built on seven drugs — not science, but scale.

Bristol Myers Squibb is not a story of scientific breakthrough but of industrial continuity: two 19th-century drugmakers merged in 1989, retained their WWII-era production logic, and now depend on seven high-revenue drugs sold overwhelmingly in one country.

CompaniesMedicinePhysicsChemistryMedicine across the network →
Chapters & takeaways4
  1. 1:03
    The Merger Was Not a Pivot

    The 1989 merger was administrative consolidation, not strategic reinvention.

  2. 2:40
    Seven Drugs, Eighty-Two Percent

    Eighty-two percent of 2025 revenue comes from just seven drugs — all biologics or small molecules targeting narrow indications.

  3. 4:32
    One Market, Two-Thirds of Revenue

    The US accounts for 69% of revenue — no other country or region is named, measured, or disclosed.

  4. 6:10
    Penicillin Plants, Not Pipelines

    Both predecessor companies scaled wartime penicillin production — Squibb in New Brunswick, Bristol-Myers in East Syracuse — establishing a pattern of industrial capacity over discovery.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • US commercial execution
  • therapeutic pairing (Opdivo + Yervoy)
  • revenue concentration as a defensible position
What does not
  • innovate in delivery models
  • disclose cost structure
  • diversify outside oncology and haematology
  • generate material revenue outside the US
Study it if
  • students of pharmaceutical economics
  • analysts of geographic revenue risk
  • historians of industrial medicine
Skip it if
  • founders seeking innovation playbooks
  • investors assessing global scalability
  • policymakers evaluating pricing transparency
The written brief1 min read

What the company or idea is

Bristol Myers Squibb is an American multinational pharmaceutical company formed in 1989 by the merger of two older firms: Squibb (founded 1858) and Bristol-Myers (founded 1887).

How it actually makes money

It makes money by selling patented prescription drugs in the United States, where 69% of its 2025 revenues come from. Its top seven products — Eliquis, Opdivo, Revlimid, Orencia, Pomalyst/Imnovid, Yervoy, and Reblozyl — account for 82% of 2025 revenues.

What works

Its commercial execution works: Eliquis alone delivers 30% of 2025 revenues. Its regulatory strategy works: Opdivo and Yervoy were co-developed to target complementary immune checkpoints, enabling combination use. Its US market dominance works: it leverages payer systems, formularies, and physician networks more deeply than any non-US geography.

What does not

It does not diversify geographically: nearly seven in ten dollars come from the US. It does not broaden its pipeline beyond oncology and haematology: six of its seven top products treat cancer or blood disorders. It does not disclose manufacturing costs, R&D spend per drug, or pricing logic — only revenue shares.

What to take from it

The 1989 merger did not produce a new business model — it consolidated two established manufacturers with parallel WWII-era penicillin production histories into a single entity whose modern revenue depends almost entirely on seven drugs, most approved after 2010.

Is it worth your time

Yes, if you are studying how legacy pharmaceutical mergers create revenue concentration in a single market while relying on narrow therapeutic portfolios — not as a model of innovation, but as a case study in scale-through-acquisition and geographic dependency.

Same desk · Companies4 of 208
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
10:55
Air Canada1937Air Canada is Canada’s state-founded, privatised, hub-based flag carrier—large by fleet and passengers, anchored in Montreal, Toronto, and Vancouver, and embedded in Star Alliance. It carried 45.3 million passengers in 2025. It was founded in 1937 as Trans-Canada Air Lines, renamed in 1965, privatised in 1988, acquired Canadian Airlines in 2000, and filed for bankruptcy protection in 2003 before emerging in 2004.
Up next in Business

British Airways

Albert Stanley · 1919 · 9:46

A state-built airline turned private monopoly — profitable on paper, broken in practice.

Play nextBack to Companies
9:46